Spero Therapeutics, Inc. (SPRO)

2.315 +0.04 (+1.98%) USD  |  NASDAQ  |  Dec 17, 16:00
2.315 0.00 (0.00%) After-Hours: 18:38
More

Spero Therapeutics Research and Development Expense (Quarterly): 8.597M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for SPRO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Omeros Corp. 15.76M
GeoVax Labs, Inc. 5.044M
Vistagen Therapeutics, Inc. 15.86M
Daré Bioscience, Inc. 0.6933M
Hyperion DeFi, Inc. 0.3739M